Key Findings

SIR-Spheres® Y-90 resin microspheres + mFOLFOX6 +/- biological*

  • did not add a benefit in Overall Survival1, but:
  • significantly increased Response Rate and median Progression Free Survival in the liver,1,2
  • resulted in a clinically relevant improvement in Overall Survival in patients with liver metastases from Right Sided Primary (RSP) tumours,
  • showed a Safety and Tolerability profile as expected and manageable.

*Bevacizumab in SIRFLOX and FOXFIRE Global, bevacizumab or cetuximab in FOXFIRE and biologicals allowed at investigator’s discretion, per institutional practice.

1. Wasan HS et al. Lancet Oncol 2017; 18: 1159-71
2. Van Hazel G et al. J Clin Oncol 2016; 34:1723–1731.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.